Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)
NCT ID: NCT01077843
Last Updated: 2022-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
27381 participants
OBSERVATIONAL
2009-08-17
2015-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of the study is to describe in European participants with AS: 1) the use of etoricoxib 2) characteristics of those who use etoricoxib. 3) the safety profile of etoricoxib and other anti-inflammatory therapies with respect to specific clinical outcomes of interest relative to non-use of these medications and relative to each other.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)
NCT01327638
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
NCT01208207
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
NCT01208181
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
NCT01786668
A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis
NCT04713072
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure
Ankylosing spondylitis patients currently exposed to anti-inflammatory treatments
Etoricoxib
Cox-2 inhibitor
Other Cox-2 inhibitors
Cox-2 inhibitor
Other Non-selective NSAIDs
Non-selective NSAID
Non-exposure
Ankylosing spondylitis patients not currently exposed to anti-inflammatory treatments
No anti-inflammatory treatment
No anti-inflammatory prescription
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etoricoxib
Cox-2 inhibitor
Other Cox-2 inhibitors
Cox-2 inhibitor
Other Non-selective NSAIDs
Non-selective NSAID
No anti-inflammatory treatment
No anti-inflammatory prescription
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A recorded AS diagnosis following the applicable "acceptable data quality" date for the database that contains the patient's records
* At least 6 months of registered medical records in the database after the applicable "acceptable data quality" date as described above, and prior to the recorded AS diagnosis
* Complete information on gender and birth year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon and Co
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Related Links
Access external resources that provide additional context or updates about the study.
EU PAS Register (EUPAS19094)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0663-163
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.